Brief: VectivBio Presents Data Supporting Apraglutide For Treatment Of SBS-IF Patients With Renal Dysfunction

VectivBio Holding AG

29/03/2022 12:50

March 29 (Reuters) - VectivBio Holding AG  VECT.O :
    * VECTIVBIO PRESENTS NEW CLINICAL DATA SUPPORTING
APRAGLUTIDE FOR
TREATMENT OF SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE
(SBS-IF) PATIENTS WHO HAVE RENAL DYSFUNCTION AT THE 2022
AMERICAN SOCIETY OF PARENTERAL AND ENTERAL NUTRITION CONFERENCE
    * VECTIVBIO HOLDING AG- APRAGLUTIDE WELL-TOLERATED AND DOES
NOT
REQUIRE DOSE-ADJUSTMENT IN PATIENTS WITH SEVERE RENAL DISEASE
    * VECTIVBIO HOLDING AG- RESULTS DEMONSTRATE POTENTIAL TO
REACH 28%
OF SBS-IF PATIENTS WITH RENAL DYSFUNCTION WHO ARE UNDERSERVED BY
CURRENTLY AVAILABLE THERAPIES

Source text for Eikon:  ID:nGNX765qZQ 
Further company coverage:  VECT.O 

 ((Reuters.Briefs@thomsonreuters.com;))